Edarbyclor generic
Edarbyclor is an antihypertensive drug owned by Azurity. It contains Azilsartan Kamedoxomil and Chlorthalidone as active ingredients. Azilsartan is an angiotensin II receptor blocker that slows down the activity of certain chemicals that tighten the blood vessels, making blood flow more smoothly. Chlorthalidone is a diuretic that helps reduce the amount of water in the body by increasing the flow of urine, which helps lower blood pressure. Edarbyclor was first authorized for market use on December 20, 2011.
When will Edarbyclor generic be available?
The generics of Edarbyclor are anticipated to be released after July 1, 2031, once the last patent of the drug expires. It's therefore important for patients and healthcare providers to stay updated about the expiration of these patents and the availability of the generic version.
Edarbyclor uses
Edarbyclor is primarily used in the treatment of hypertension. The active ingredients, Azilsartan Kamedoxomil and Chlorthalidone, work synergistically - Azilsartan blocks the effects of hormones that tighten blood vessels, reducing pressure within the vessels, while Chlorthalidone promotes the elimination of water and salts from the body, thereby lowering blood volume and reducing blood pressure.
Edarbyclor patent expiration
Edarbyclor's patents are held by Azurity and are set to expire by July 1, 2031, after which generic versions of the drug will be available. The key patents governing Edarbyclor include methods of treating hypertension with an angiotensin II receptor blocker and chlorthalidone. Other important patents involve specific compositions of the drug. Below are the details of the patent: